UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.14
−3.11%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$143.04M
MomentumView details →
1D Return
−3.11%
YTD Return
−10.83%
RSI (14)
44.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$143.04M
RSI (14)
44.4
MomentumView details →
1D Return
−3.11%
YTD Return
−10.83%
SummaryUpdated Jun 1, 2026
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) is a clinical-stage biotechnology company founded in 2016 and headquartered in Los Altos, California. The company went public in July 2021 and focuses exclusively on developing innovative therapeutic treatments for kidney diseases, an area of significant unmet medical need. As a pre-revenue biotech company, Unicycive is currently advancing its pipeline of kidney-focused drug candidates through various stages of clinical development, with its lead programs targeting chronic kidney disease complications and acute kidney injury.
Similar companies
Latest newsMore news →
Unicycive Therapeutics reported its Q2 2026 financial results, with a net loss of $1.7 million and diluted EPS of -$0.06, compared to a net loss of $6.5 million in Q2 2025.24d agoThe FDA issued a second Complete Response Letter to Unicycive Therapeutics regarding the resubmitted OLC NDA, citing the same third-party manufacturing deficiencies as in the prior CRL.66d ago